RecruitingNon Small Cell Lung Cancer
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation of osimertinib treatment (\~30%) will undergo imaging with standardized intervals.
Sponsor: N-Power Medicine
You may qualify if…
- ✓ Be ≥18 years of age at the time of informed consent
- ✓ Evidence of a confirmed diagnosis of EGFR mutant (EGFR exon 19del or EGFR exon 21 L858R) locally advanced or metastatic NSCLC diagnosed on Jan 1st 2024 or later.
You may not qualify if…
- ✕ ECOG≥2 at diagnosis of advanced or metastatic NSCLC
- ✕ Evidence of prior treatment with osimertinib, amivantamab or lazertinib. For the planned selection and analysis of external controls, further eligibility criteria will be applied according to the COPERNICUS SAP.
Where it's recruiting
California
Monterey · Torrance
Delaware
Dover · Milford
Idaho
Coeur d'Alene
Illinois
Elk Grove Village
Pennsylvania
Paoli
Texas
Houston
Source: ClinicalTrials.gov · NCT07028489 · last updated 2026-06-16